Azithromycin & Streptococcal pharyngitis

Regulatory status

FDA status

In the context of Azithromycin & Streptococcal pharyngitis, the FDA‑approved labeling for azithromycin lists pharyngitis/tonsillitis caused by Streptococcus pyogenes as an indication, for patients ≥2 years of age. It is generally indicated as an alternative to first‑line therapy (e.g., penicillin or amoxicillin) in patients who cannot use those agents, consistent with regulatory summaries of FDA‑approved indications (1, 2).

EMA status

EMA’s CHMP has concluded that the benefit–risk balance of azithromycin‑containing products remains positive for acut…